|
Volumn 52, Issue 2, 2001, Pages 149-156
|
Fotemustine combined with procarbazine in recurrent malignant gliomas: A phase I study with evaluation of lymphocyte O6-alkylguanine-DNA alkyltransferase activity
a a a b b c c c |
Author keywords
Fotemustine; Malignant glioma; O6 alkylguanine DNA alkyltransferase; Phase I study; Procarbazine
|
Indexed keywords
6 O ALKYLGUANINE DNA ALKYLTRANSFERASE;
CORTICOSTEROID;
FOTEMUSTINE;
NITROSOUREA DERIVATIVE;
PROCARBAZINE;
ADULT;
AGED;
ANEMIA;
ARTICLE;
BONE MARROW SUPPRESSION;
CANCER CONTROL;
CANCER RECURRENCE;
CANCER SURVIVAL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
DEPLETION;
DISEASE COURSE;
DOSE CALCULATION;
DOSE RESPONSE;
DRUG EFFECT;
DRUG MECHANISM;
DRUG TOLERABILITY;
ENZYME ACTIVITY;
FEMALE;
GLIOMA;
HUMAN;
LYMPHOCYTE FUNCTION;
MAINTENANCE THERAPY;
MAXIMUM TOLERATED DOSE;
NEUTROPENIA;
PHASE 1 CLINICAL TRIAL;
THROMBOCYTOPENIA;
VALIDATION PROCESS;
ADULT;
AGED;
ANTINEOPLASTIC AGENTS;
BRAIN NEOPLASMS;
FEMALE;
GLIOMA;
HUMANS;
LYMPHOCYTES;
MALE;
MIDDLE AGED;
NEOPLASM RECURRENCE, LOCAL;
NITROSOUREA COMPOUNDS;
O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;
ORGANOPHOSPHORUS COMPOUNDS;
PROCARBAZINE;
|
EID: 0034915241
PISSN: 0167594X
EISSN: None
Source Type: Journal
DOI: 10.1023/A:1010626421709 Document Type: Article |
Times cited : (13)
|
References (34)
|